Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations

Genetics in Medicine

Volumn 18, Issue 12, 2016, Pages 1171-1180

  D'Andrea, Elvira ^a   Marzuillo, Carolina ^a   De Vito, Corrado ^a   Di Marco, Marco ^a   Pitini, Erica ^a   Vacchio, Maria Rosaria ^a   Villari, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BRCA; breast cancer; cost effectiveness; health care programs; systematic review

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN;

ASHKENAZI JEW; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; ECONOMIC EVALUATION; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; OVARY CANCER; PROGRAM COST EFFECTIVENESS; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; BREAST NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; GENETICS; JEW; MUTATION; OVARIAN NEOPLASMS; RISK ASSESSMENT;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; JEWS; MASS SCREENING; MUTATION; OVARIAN NEOPLASMS; RISK ASSESSMENT;

EID: 85000460244     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2016.29     Document Type: Review

References (51)

1. Centers for Disease Control, Prevention. Public Health Genomics. Genomic Tests, Family History by Levels of Evidence. www.cdc.gov/genomics/gtesting/tier.htm. Accessed 5 August 2015.
2. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med 2010;12:680-683.
3. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care, disease prevention Genet Med 2007;9:665-674.
4. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Public Health Genom 2011;14:1-8.
5. Khoury MJ, Coates RJ, Fennell ML, et al. Multilevel research, the challenges of implementing genomic medicine. J Natl Cancer Inst Monogr 2012;2012:112-120.
6. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Oxford University Press: Oxford, UK, 2005.
7. Anglian Breast Cancer Study Group. Prevalence, penetrance of BRCA1, BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 2000;83:1301-1308.
8. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1, BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-2816.
9. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1, BRCA2 mutation frequencies, cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706.
10. Ministry of Health. 2014-2018 National Prevention Plan, Italy. www.salute.gov. it/portale/documentazione/p6-2-2-1.jsplingua=italiano&id=2285. Accessed 5 August 2015.
11. Anderson R. Systematic reviews of economic evaluations: utility or futility Health Econ 2010;19:350-364.
12. Centre for Reviews, Dissemination (CRD). Systematic reviews of economic evaluations. In: Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. CRD: York, UK, 2009.
13. Shemilt I, Mugford M, Byford S, et al. Incorporating economics evidence. In: Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0. The Cochrane Collaboration, 2011. http://handbook.cochrane.org/
14. Drummond MF, Jefferson TO. Guidelines for authors, peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-283.
15. Chiou CF, Hay JW, Wallace JF, et al. Development, validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41:32-44.
16. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37-46.
17. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-The curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-797.
18. Phillips KA, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know, what we need to know. Genet Med 2014;16:251-257.
19. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold. Health Technol Assess 2015;19(14):1-503.
20. Center for the Evaluation of Value, Risk in Health at the Institute for Clinical Research, Health Policy Studies. Cost-Effectiveness Analysis Registry (https://research.tufts-nemc.org/cear4/). Tufts Medical Center: Boston, MA, 2015. Accessed 5 August, 2015.
21. Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits, costs of screening Ashkenazi Jewish women for BRCA1, BRCA2. J Clin Oncol 1999;17:494-500.
22. Heimdal K, Maehle L, Møller P. Costs, benefits of diagnosing familial breast cancer. Dis Markers 1999;15:167-173.
23. Tengs TO, Berry DA. The cost effectiveness of testing for the BRCA1, BRCA2 breast-ovarian cancer susceptibility genes. Dis Manag Clin Outcomes 2000;1:15-24.
24. Balmanã J, Sanz J, Bonfill X, et al. Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost, cost-effectiveness ratio. Int J Cancer 2004;112:647-652.
25. Holland ML, Huston A, Noyes K. Cost-effectiveness of testing for breast cancer susceptibility genes. Value Health 2009;12:207-216.
26. Kwon JS, Daniels MS, Sun CC, Lu KH. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J Clin Oncol 2010;28: 675-682.
27. Rubinstein WS, Jiang H, Dellefave L, Rademaker AW. Cost-effectiveness of population-based BRCA1/2 testing, ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genet Med 2009;11:629-639.
28. Kwon JS, Gutierrez-Barrera AM, Young D, et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. J Clin Oncol 2010;28:4214-4220.
29. Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 2015;107:380.
30. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews, meta-analyses of studies that evaluate healthcare interventions: explanation, elaboration. BMJ 2009;339:b2700.
31. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1, BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
32. Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-190.
33. Tonin P, Weber B, Offit K, et al. Frequency of recurrent BRCA1, BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med 1996;2: 1179-1183.
34. European Society of Human Genetics (ESHG). Population genetic screening programmes: technical, social, ethical issues. Recommendations of the European Society of Human Genetics. Eur J Hum Genet 2003;11:S5-S7.
35. Giacomini M, Miller F, O'Brien BJ. Economic considerations for health insurance coverage of emerging genetic tests. Community Genet 2003;6:61-73.
36. Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genet Med 2005;7:519-523.
37. Rogowski W. Genetic screening by DNA technology: a systematic review of health economic evidence. Int J Technol Assess Health Care 2006;22:327-337.
38. Djalalov S, Musa Z, Mendelson M, Siminovitch K, Hoch J. A review of economic evaluations of genetic testing services, interventions (2004-2009). Genet Med 2011;13:89-94.
39. Assasi N, Schwartz L, Tarride JE, Goeree R, Xie F. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. Genet Test Mol Biomarkers 2012;16:1322-1335.
40. D'Andrea E, Marzuillo C, Pelone F, De Vito C, Villari P. Genetic testing, economic evaluations: a systematic review of the literature. Epidemiol Prev 2015;39(suppl 1):S45-S50.
41. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money Health economics, the presidential candidates. N Engl J Med 2008;358: 661-663.
42. Chokshi DA, Farley TA. The cost-effectiveness of environmental approaches to disease prevention. N Engl J Med 2012;367:295-297.
43. Sullivan W, Evans DG, Newman WG, Ramsden SC, Scheffer H, Payne K. Developing national guidance on genetic testing for breast cancer predisposition: the role of economic evidence Genet Test Mol Biomarkers 2012;16:580-591.
44. Long EF, Ganz PA. Cost-effectiveness of universal BRCA1/2 screening: evidencebased decision making. JAMA Oncol 2015;3:1-2.
45. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN Task Force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;9(suppl 5):S1-S32; quiz S33.
46. US Preventive Services Task Force (USPSTF). Risk Assessment, Genetic Counseling, Genetic Testing for BRCA-Related Cancer. Systematic Review to Update the US Preventive Services Task Force Recommendation. Evidence Syntheses, No. 101. Agency for Healthcare Research, Quality (US): Rockville, MD, 2013.
47. Bellcross CA, Kolor K, Goddard KA, Coates RJ, Reyes M, Khoury MJ. Awareness, utilization of BRCA1/2 testing among US primary care physicians. Am J Prev Med 2011;40:61-66.
48. Marzuillo C, De Vito C, Boccia S, et al. Knowledge, attitudes, behavior of physicians regarding predictive genetic tests for breast, colorectal cancer. Prev Med 2013;57:477-482.
49. Grosse SD. Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med 2014;16:225-227.
50. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104.
51. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79.